Suppr超能文献

2020 年至 2044 年澳大利亚的癌症发病率和死亡率,以及对 COVID-19 大流行期间治疗延迟潜在影响的探索性分析:一项统计建模研究。

Cancer incidence and mortality in Australia from 2020 to 2044 and an exploratory analysis of the potential effect of treatment delays during the COVID-19 pandemic: a statistical modelling study.

机构信息

The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, NSW, Australia.

The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, NSW, Australia; School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia.

出版信息

Lancet Public Health. 2022 Jun;7(6):e537-e548. doi: 10.1016/S2468-2667(22)00090-1.

Abstract

BACKGROUND

Long-term projections of cancer incidence and mortality estimate the future burden of cancer in a population, and can be of great use in informing the planning of health services and the management of resources. We aimed to estimate incidence and mortality rates and numbers of new cases and deaths up until 2044 for all cancers combined and for 21 individual cancer types in Australia. We also illustrate the potential effect of treatment delays due to the COVID-19 pandemic on future colorectal cancer mortality rates.

METHODS

In this statistical modelling study, cancer incidence and mortality rates in Australia from 2020 to 2044 were projected based on data up to 2017 and 2019, respectively. Cigarette smoking exposure (1945-2019), participation rates in the breast cancer screening programme (1996-2019), and prostate-specific antigen testing rates (1994-2020) were included where relevant. The baseline projection model using an age-period-cohort model or generalised linear model for each cancer type was selected based on model fit statistics and validation with pre-COVID-19 observed data. To assess the impact of treatment delays during the COVID-19 pandemic on colorectal cancer mortality, we obtained data on incidence, survival, prevalence, and cancer treatment for colorectal cancer from different authorities. The relative risks of death due to system-caused treatment delays were derived from a published systematic review. Numbers of excess colorectal cancer deaths were estimated using the relative risk of death per week of treatment delay and different durations of delay under a number of hypothetical scenarios.

FINDINGS

Projections indicate that in the absence of the COVID-19 pandemic effects, the age-standardised incidence rate for all cancers combined for males would decline over 2020-44, and for females the incidence rate would be relatively stable in Australia. The mortality rates for all cancers combined for both males and females are expected to continuously decline during 2020-44. The total number of new cases are projected to increase by 47·4% (95% uncertainty interval [UI] 35·2-61·3) for males, from 380 306 in 2015-19 to 560 744 (95% UI 514 244-613 356) in 2040-44, and by 54·4% (95% UI 40·2-70·5) for females, from 313 263 in 2015-19 to 483 527 (95% UI 439 069-534 090) in 2040-44. The number of cancer deaths are projected to increase by 36·4% (95% UI 15·3-63·9) for males, from 132 440 in 2015-19 to 180 663 (95% UI 152 719-217 126) in 2040-44, and by 36·6% (95% UI 15·8-64·1) for females, from 102 103 in 2015-19 to 139 482 (95% UI 118 186-167 527) in 2040-44, due to population ageing and growth. The example COVID-19 pandemic scenario of a 6-month health-care system disruption with 16-week treatment delays for colorectal cancer patients could result in 460 (95% UI 338-595) additional deaths and 437 (95% UI 314-570) deaths occurring earlier than expected in 2020-44.

INTERPRETATION

These projections can inform health service planning for cancer care and treatment in Australia. Despite the continuous decline in cancer mortality rates, and the decline or plateau in incidence rates, our projections suggest an overall 51% increase in the number of new cancer cases and a 36% increase in the number of cancer deaths over the 25-year projection period. This means that continued efforts to increase screening uptake and to control risk factors, including smoking exposure, obesity, physical inactivity, alcohol use, and infections, must remain public health priorities.

FUNDING

Partly funded by Cancer Council Australia.

摘要

背景

长期的癌症发病率和死亡率预测可以估算一个人群中的癌症未来负担,这对于卫生服务规划和资源管理非常有用。我们旨在估计澳大利亚所有癌症和 21 种特定癌症类型的发病率和死亡率以及新发病例和死亡人数,直至 2044 年。我们还说明了由于 COVID-19 大流行导致的治疗延迟对未来结直肠癌死亡率的潜在影响。

方法

在这项统计建模研究中,根据截至 2017 年和 2019 年的数据,预测了澳大利亚 2020 年至 2044 年的癌症发病率和死亡率。在相关情况下,纳入了吸烟暴露(1945-2019 年)、乳腺癌筛查计划参与率(1996-2019 年)和前列腺特异性抗原检测率(1994-2020 年)。根据模型拟合统计数据和与 COVID-19 前观察数据的验证,选择了使用年龄-时期-队列模型或广义线性模型的基本预测模型来对每种癌症类型进行预测。为了评估 COVID-19 大流行期间治疗延迟对结直肠癌死亡率的影响,我们从不同权威机构获得了结直肠癌的发病、生存、流行和癌症治疗数据。通过一项已发表的系统评价,得出了由于系统引起的治疗延迟而导致死亡的相对风险。使用每周治疗延迟和多种假设情况下不同延迟持续时间的治疗延迟导致的死亡相对风险,估计了结直肠癌死亡人数的增加。

结果

预测表明,如果没有 COVID-19 大流行的影响,澳大利亚男性所有癌症的年龄标准化发病率在 2020-44 年期间将下降,而女性的发病率在澳大利亚将相对稳定。预计 2020-44 年期间,所有癌症的男性和女性的死亡率将持续下降。预计男性的新发病例总数将增加 47.4%(95%不确定性区间[UI]为 35.2-61.3),从 2015-19 年的 380306 例增加到 2040-44 年的 560744 例(95%UI 为 514244-613356),女性的新发病例总数将增加 54.4%(95%UI 为 40.2-70.5),从 2015-19 年的 313263 例增加到 2040-44 年的 483527 例(95%UI 为 439069-534090)。预计男性的癌症死亡人数将增加 36.4%(95%UI 为 15.3-63.9),从 2015-19 年的 132440 例增加到 2040-44 年的 180663 例(95%UI 为 152719-217126),女性的癌症死亡人数将增加 36.6%(95%UI 为 15.8-64.1),从 2015-19 年的 102103 例增加到 2040-44 年的 139482 例(95%UI 为 118186-167527),这主要是由于人口老龄化和增长。在 COVID-19 大流行的情况下,如果医疗保健系统中断 6 个月,结直肠癌患者的治疗延迟 16 周,那么在 2020-44 年期间,可能会导致 460(95%UI 为 338-595)例额外死亡和 437(95%UI 为 314-570)例提前死亡。

解释

这些预测可以为澳大利亚的癌症护理和治疗提供卫生服务规划信息。尽管癌症死亡率持续下降,而且发病率也呈下降或稳定趋势,但我们的预测显示,在 25 年的预测期内,新发病例的总数将增加 51%,癌症死亡人数将增加 36%。这意味着,继续努力提高筛查参与率并控制包括吸烟暴露、肥胖、缺乏身体活动、饮酒和感染在内的风险因素,仍然是公共卫生的重点。

资助

部分由澳大利亚癌症委员会资助。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/177e/9178213/c3a9594b06a5/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验